Bayer's 2026 Pivot: Pipeline Promise Meets Patent Pressure

Bayer navigates near-term cash flow and patent pressures while banking on drugs like Nubeqa and Kerendia for a post-2026 recovery. Analysts show cautious optimism.

Bayer's stock, trading at €40.74, finds itself at a crossroads. While the share price sits roughly 17% below its 52-week high of €49.17, a complex narrative of near-term challenges and long-term promises is unfolding. The company is navigating a dense calendar of events, headlined by its virtual Annual General Meeting on April 24, followed closely by first-quarter results.

The upcoming shareholder meeting will see a historically low dividend payout held steady at €0.11 per share, unchanged from the prior year and well below the ten-year average yield of 2.85%. It will also mark a boardroom refresh, with Marcel Smits (64) and Alfred Stern (61) slated to join the Supervisory Board as Paul Achleitner (69) and Colleen Goggins (71) depart.

Underpinning the immediate financial pressure is the structural headwind from the patent expiry of the blockbuster blood thinner Xarelto. While CFO Wolfgang Nickl confirmed some negative effects are shifting to 2026, the 2025 financials already reflect significant strain. Group revenue reached €45.6 billion, but EBITDA before special items fell 4.5% to €9.7 billion. More starkly, free cash flow plummeted by almost 33% to €2.1 billion, culminating in a net loss of €3.6 billion, largely due to substantial litigation provisions.

Yet, against this backdrop, management is projecting a turning point. The company is targeting EBITDA before special items of between €9.6 billion and €10.1 billion for 2026, with net financial debt having already decreased by 8.5% year-on-year to €29.8 billion at the end of 2025.

The foundation for a post-2026 recovery, according to Pharma chief Stefan Oelrich, lies in a record pipeline and two established growth drivers. The prostate cancer drug Nubeqa saw sales surge 57% in 2025 to €2.4 billion, now treating over 200,000 patients globally with a third approved indication. The kidney disease medication Kerendia was even more dynamic, posting a 79% annual sales increase to €829 million, with fourth-quarter growth hitting 93%. Bayer sees a long-term peak sales potential of €3 billion for Kerendia.

This commercial momentum is bolstered by recent R&D success, including five regulatory approvals in 2025 and six positive Phase III study readouts. A key highlight is Asundexian, a Factor XIa inhibitor with positive Phase III data for stroke prevention, which Bayer touts as the first successful study of its kind for this drug class.

External risks, such as new U.S. import tariffs on pharmaceuticals, are not seen as derailing the annual forecast, according to Pharma COO Sebastian Guth. Existing trade agreements cap tariffs on most goods at 15%, and Bayer maintains its guidance for currency-adjusted sales of €45 to €47 billion alongside its EBITDA target.

Analyst sentiment appears cautiously optimistic relative to the current share price. UBS maintains a Buy rating with a €52 price target, while DZ Bank recently upgraded the stock from Sell to Hold, raising its fair value estimate to €44. On the sustainability front, Bayer received an inaugural AA rating from MSCI Solutions, and Sustainalytics removed its "Red Flag" assessment, signaling a view that glyphosate litigation risks are now more manageable.

The coming weeks will test investor conviction. The AGM and subsequent Q1 report, with a sharp focus on Nubeqa and Kerendia performance, will provide critical data points. Bayer's thesis is clear: 2026 represents the final year of material patent headwinds from Xarelto and Eylea, setting the stage for mid-single-digit sales growth in the Pharma division from 2027 onward, with ambitions for operating margins nearing 30% by 2030. The market is now counting down to evidence that this promised pivot is on track.